Abstract
The 1996 World Health Organization (WHO) recommendations for mild hypertension stressed the need to evaluate target-organ lesions as treatment criteria. The effects of both vascular and heart remodelling on hypertension must to be taken into account, as they adversely influence the prognosis of patients with hypertension. It was previously demonstrated that at least three classes of antihypertensive agents were able to decrease morbidity and mortality in patients with hypertension. Meta-analyses have shown that angiotensin-converting enzyme inhibitors seem to have a marked effect on regression of left ventricular hypertrophy (LVH). However, the relationship between drug-induced LVH regression and reduced morbidity and mortality remains to be confirmed. The effect of antihypertensive agents on vascular hypertrophy, as assessed by intima-media thickness, and their involvement in reducing morbid events, also have to be determined at the vascular level. As experimental data have highlighted the involvement of angiotensin II in animal models of LVH and vascular hypertrophy development, the role of angiotensin II AT1 receptor blockers should also be assessed in this indication.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mallion, JM., Baguet, JP., Siche, JP. et al. Cardiac and vascular remodelling: effect of antihypertensive agents. J Hum Hypertens 13 (Suppl 1), S35–S41 (1999). https://doi.org/10.1038/sj.jhh.1000755
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1000755
- Springer Nature Limited